Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	76.33	109.11	112.58	85.21	29.73
Short-Term Investments	0	0	33.82	41.7	52.32
Cash & Cash Equivalents	76.33	109.11	146.4	126.91	82.05
Cash Growth	-30.04%	-25.47%	15.36%	54.68%	-28.93%
Receivables	97.29	1.08	2.64	5.33	7.76
Other Current Assets	-42.41	3.38	8.83	6.91	5.61
Total Current Assets	131.21	113.57	157.87	139.15	95.41
Property, Plant & Equipment	4.16	5.49	7.56	8.78	7.15
Other Long-Term Assets	47.03	5.74	5.64	5.52	3.54
Total Long-Term Assets	51.18	11.23	13.2	14.31	10.69
Total Assets	182.39	124.8	171.07	153.45	106.1
Accounts Payable	1.38	0.62	1.1	1.16	4.15
Deferred Revenue	61.54	32.54	10.64	0	0
Current Debt	1.72	1.69	1.36	0.95	0.93
Other Current Liabilities	-27.49	-13.19	5.56	12.24	21.59
Total Current Liabilities	37.15	21.65	18.67	14.34	26.66
Long-Term Debt	3.83	4.96	5.97	6.89	4.62
Other Long-Term Liabilities	34.52	22.26	58.14	0.18	0.25
Total Long-Term Liabilities	38.34	27.22	64.11	7.07	4.87
Total Liabilities	75.5	48.87	82.78	21.41	31.53
Total Debt	5.54	6.65	7.34	7.84	5.55
Debt Growth	-16.61%	-9.38%	-6.42%	41.35%	-
Retained Earnings	-391.07	-413.88	-367.46	-277.71	-199.43
Comprehensive Income	0	0	-0	-0.01	0.02
Shareholders' Equity	106.89	75.93	88.29	132.04	74.57
Net Cash / Debt	70.79	102.46	139.07	119.07	76.5
Net Cash / Debt Growth	-30.91%	-26.32%	16.80%	55.64%	-33.73%
Net Cash Per Share	1.34	2.73	4.50	5.32	4.21
Working Capital	94.06	91.92	139.2	124.8	68.75
Book Value Per Share	2.03	2.02	2.86	5.90	4.11

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).